UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM S-8

 

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

 

IMMUNE THERAPEUTICS, INC.

(Exact name of registrant as specified in charter)

 

Florida

  59-3226705

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

     
37 North Orange Ave, Suite 607 Orlando, FL   32801
(Address of principal executive offices)   (Zip Code)

 

Independent Corporate Development and Legal Advising Agreement executed December 6, 2017

(Full title of plan)

 

Noreen Griffin
Chief Executive Officer of Immune Therapeutics, Inc.

37 North Orange Ave, Suite 607, Orlando, FL 32801

(Name and address of agent for service)

 

888-613-8802

(Telephone number, including area code, of agent for service)

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

  Large accelerated filer [  ]   Accelerated filer [  ]
  Non-accelerated filer [  ]   Smaller reporting company [X]
      Emerging growth company [X]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. [  ]

 

CALCULATION OF REGISTRATION FEE

 

Title of securities to be registered   Amount to be registered   Proposed maximum offering price per share     Proposed maximum aggregate offering price     Amount of registration fee(2)  
Common Stock, par value $0.0001 per share (1)   3,000,000 shares   $ 0.0108     $ 32,400.00     $ 3.93  

 

  (1) The aggregate amount of securities registered hereunder is 3,000,000 shares of Common Stock of Immune Therapeutics, Inc., a Florida corporation (the “Registrant”, “Company”, “us”, “our” or “we”) to be issued upon the grant of awards pursuant to the Independent Corporate Development and Legal Advising Agreement executed on December 6, 2017 (the “Advising Agreement”). In addition, pursuant to Rule 416(c) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8 (this “Registration Statement”) filed by the Company, shall also cover additional shares of common stock which may become issuable by reason of any stock split, stock dividend, recapitalization or other similar transactions effected without consideration which results in an increase in the number of the Registrant’s shares of outstanding common stock.
     
  (2) The fee is calculated by multiplying the aggregate offering amount by .0001212.

 

 

 

     
 

 

PART I

 

INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

 

This Registration Statement relates to the issuance of up to 3,000,000 shares of the Company’s common stock to an individual independent contractor of the Company (the “Participant”) pursuant to an Independent Corporate Development and Legal Advising Agreement, dated December 6, 2017, between, inter alia , the Company and Participant.

 

Item 1 Plan Information.*

 

Item 2 Registrant Information and Employee Plan Annual Information.*

 

*The information specified in Part I of this Registration Statement on Form S-8 is omitted from this filing in accordance with the provisions of Rule 428 under the Securities Act and the introductory note to Part I of the Registration Statement on Form S-8. The documents containing the information specified in Part I will be delivered to the participants covered by this Registration Statement as required by Rule 428(b)(1).

 

PART II

 

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

 

Item 3. Incorporation of Documents by Reference.

 

The SEC allows us to “incorporate by reference” the information we file with the SEC, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this Registration Statement, and later information filed with the SEC will update and supersede this information. We hereby incorporate by reference into this Registration Statement the following documents previously filed with the SEC:

 

  a. The Registrant’s Annual Report on Form 10-K for the annual period ended December 31, 2017;
  b. The Registrant’s Quarterly Report on Form 10-Q filed on May 15, 2018;
  c. The Registrant’s Quarterly Report on Form 10-Q filed on August 14, 2018;
  d. The Registrant’s Current Reports on Form 8-K (excluding any reports or portions thereof that are deemed to be furnished and not filed) filed on March 28, 2018, April 27, 2018, May 55, 2018, and June 11, 2018, respectively; and
  e. The description of the Registrant’s Common Stock is contained in our Form S-1, filed on October 14, 2016, and its amendments filed on November 10, 2016 and December 1, 2016, respectively.

 

Except to the extent that information therein is deemed furnished and not filed pursuant to the Exchange Act, all documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act subsequent to the effective date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement indicating that all securities offered hereby have been sold or deregistering all securities then remaining unsold shall be deemed to be incorporated by reference herein and to be a part hereof from the date of filing of such documents. Any statement contained herein or in any document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed to constitute a part of this Registration Statement, except as so modified or superseded.

 

Item 4. Description of Securities.

 

Not Applicable.

 

Item 5. Interests of Named Experts and Counsel.

 

Not Applicable.

 

  2  
 

 

Item 6. Indemnification of Directors and Officers.

 

Under our Articles of Incorporation and Bylaws, we will indemnify, to the extent allowed under Florida Statutes, an officer or director who is made a party to any proceeding, including a lawsuit, because of their position. We must advance expenses incurred in defending a proceeding. The person to be indemnified must have acted in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the conduct was unlawful.

 

Section 607.0850 of the 2017 Florida Statutes provides that our officers and directors will not be liable to us or our stockholders for monetary damages for all but certain types of conduct as officers and directors. Our Bylaws permit us broad indemnification powers to all persons against all damages incurred in connection with our business to the fullest extent provided or allowed by law. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Company pursuant to the provisions of Florida law, the Registrant has been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.

 

Item 7. Exemption from Registration Claimed.

 

Not Applicable.

 

Item 8. Exhibits.

 

The Exhibit Index immediately preceding the exhibits is incorporated herein by reference.

 

Item 9. Undertakings.

 

(a) The Registrant hereby undertakes:

 

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

 

(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

 

(ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement;

 

(iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

 

Provided, however , that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the Registration Statement is on Form S-8 and the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the SEC by the Registrant pursuant to Section 13 or 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

 

(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new Registration Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

  3  
 

 

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

 

(b) The Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new Registration Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

(h) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

 

  4  
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Orlando, State of Florida, on October 15, 2018.

 

  Immune Therapeutics, Inc.
       
  By: /s/ Noreen Griffin
    Noreen Griffin, Director and Chief Executive Officer
     
  By: /s/ Peter Aronstam
    Peter Aronstam, Principal Accounting Officer

 

POWER OF ATTORNEY

 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Noreen Griffin and Peter Aronstam, and each of them, with full power of substitution, his or her true and lawful attorney-in-fact to act for him or her in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file each of the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in order to effectuate the same as fully, to all intents and purposes, as he or she could do in person, hereby ratifying and confirming all that said attorneys-in-fact or substitutes, or any of them, may lawfully do or cause to be done by virtue hereof.

 

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

 

October 15, 2018   /s/ Noreen Griffin
Date   Noreen Griffin, Director and Chief Executive Officer/ Principal Executive Officer
     
October 15, 2018   /s/ Edward Teraskiewicz
Date   Edward Teraskiewicz, Director

 

October 15, 2018   /s/ Jack Brewer
Date  

Jack Brewer, Director

 

October 15, 2018   /s/ Clifford Selsky
Date   Clifford Selsky, Director

 

  5  
 

 

INDEX TO EXHIBITS

 

Number   Description

4.1

 

Form of Common Stock Certificate (incorporated by reference to Registrants form S-1 filed October 14, 2016)

5.1   Opinion of Austin Legal Group, APC
23.1   Consent of Austin Legal Group, APC (included in Exhibit 5.1)
23.2  

Consent of Independent Registered Public Accounting Firm

24.1   Power of Attorney (contained on page 5 hereto)

 

  6  
 

 

 

Immune Therapeutics (PK) (USOTC:IMUN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Immune Therapeutics (PK) Charts.
Immune Therapeutics (PK) (USOTC:IMUN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Immune Therapeutics (PK) Charts.